Cannabis extract shows promise for rare genetic disorder in new trial
NCT ID NCT07257978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cannabis plant extract called NTI164, which has very low THC (the compound that causes a high), in 40 females aged 4-25 with Rett syndrome, a rare genetic condition causing severe physical and mental challenges. Participants will receive either NTI164 or a placebo, then switch after a period, to see if the treatment safely reduces symptoms like anxiety, breathing problems, and trouble communicating. The goal is to improve daily life, not to cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Monash Health
Clayton, Victoria, 3168, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A private facebook group may ease the emotional burden of caring for a child with rett syndrome
- Antioxidant cocktail may ease motor deficits in rett syndrome — a trial investigates
- Can robot legs help Non-Walking kids join in at school?
- Can early parent coaching help infants with rare genetic disorders thrive?
- Newborn screening study aims to catch rare diseases at birth
- Massive global registry aims to unlock secrets of rett syndrome